Vaxxas
PrivateLast Round
Debt
Aug 25, 2025
Est. Valuation
$805M
Total Funding Raised
$168.59M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Vaxxas is a biotechnology company that develops a needle-free, patch-based vaccine delivery technology designed to improve vaccine performance and stability.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting, Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vaxxas Comparables
Compare Vaxxas with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Micron Biomedical | 88% | |
| PharmaJet | 82% | |
| Verndari, Inc. | 82% | |
Vaxxas Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Aug 25, 2025 | ||||
| Series D | Aug 25, 2025 | ||||
| VC Round | Dec 5, 2022 | ||||
| Grant | Oct 1, 2022 | ||||
| Grant | May 28, 2020 | ||||
Series B | Apr 1, 2017 |
Key People
Founding team and executive leadership
Vaxxas Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UniQuest Pty Ltd | VC Round |
| The University of Queensland | Series B |
| OneVentures | Series D, Series A, VC Round, Series B |
| CEPI | Grant |
| Queensland Government | Grant |
| HealthCare Ventures | Series A, Series B |
| SPRIM Global Investments | Series D, Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 7, 2026
David Peacock appointed as new CEO to lead commercialization.
- Nov 10, 2025
Brent MacGregor, veteran vaccine executive, joins the Board of Directors.
Vaxxas Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Vaxxas's valuation, stock price, and market status.